Fermbox Bio lands on Cleantech Group’s 2026 APAC Cleantech 25

Fermbox Bio has been named to Cleantech Group’s 2026 APAC Cleantech 25, a list of private cleantech companies across Asia-Pacific. The Bengaluru biotech is scaling precision fermentation and biomanufacturing for sustainable alternatives in flavors, enzymes and other industrial markets.

Why it matters: - Fermbox Bio’s selection signals growing recognition for precision fermentation as a manufacturing pathway for sustainable products. - The company’s platform targets supply chains that now depend on petroleum-, animal- and plant-derived inputs. - The recognition could help Fermbox Bio build credibility with customers, partners and investors across Asia-Pacific.

What happened: - Fermbox Bio was selected for Cleantech Group’s 2026 APAC Cleantech 25. - The list highlights 25 private, independent clean technology companies across Asia-Pacific. - Fermbox Bio is based in Bengaluru, Karnataka, India. - The announcement was dated June 30, 2026.

The details: - Fermbox Bio is a biotech research and manufacturing company focused on advanced biotechnology and precision fermentation. - The company uses its lab-to-launch platform, Bio-ARC, to connect product development, scale-up and manufacturing. - Bio-ARC is designed to move fermentation-derived products from concept to commercial scale. - Fermbox Bio has launched Bio-hexenol, an enzymatically derived bio-based alternative to cis-3-hexenol for the flavors and fragrances industry. - Fermbox Bio has also launched EN3ZYME, a cellulosic enzyme cocktail for 2G ethanol production. - EN3ZYME has been commercialized and is seeing active engagement with leading Indian public sector undertakings. - Fermbox Bio’s product pipeline includes enzymes, lipids, proteins, flavors and fragrances, colors and dyes, and other bio-based molecules. - Those products are aimed at industrial biotechnology, food, nutraceuticals, cosmeceuticals and life sciences. - Fermbox Bio is building a scale-led manufacturing strategy through collaborative and co-located manufacturing models. - The company says that approach is meant to support reliable supply, shorter lead times and cost-efficient biomanufacturing.

Between the lines: - The APAC Cleantech 25 was developed by Cleantech Group with APAC investors, corporates, innovation experts and its own analysts. - The list is a regional signal that cleantech is moving beyond venture-stage ideas toward commercially relevant infrastructure and materials. - Fermbox Bio’s mix of products and manufacturing strategy suggests the company is aiming to compete on both technology and supply reliability.

What's next: - Fermbox Bio is likely to keep expanding its fermentation-based product pipeline. - The company’s collaborative manufacturing model points to future scale-up as a key milestone. - Further customer adoption of EN3ZYME and other products would strengthen Fermbox Bio’s commercial profile.